Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

Belgium has solidified its position as a European leader in pharmaceutical research and development with a daily investment ...

GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

Emily Field from Barclays and Lance Wilks share insights on how RFK Jr.'s influence could affect stocks in the pharmaceutical and healthcare sectors, including companies like GSK, Sanofi, and Novo ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...